RxDoctor Payments DataLook up a doctor →

Tobias Pusch, MD

Infectious Disease · Portland, ORNPI 1811189632

Payments from drug & device makers

$1,124,425in general payments, 2019–2025

Across 368 payments — averaging $3055.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1M
  • Viiv Healthcare Company$120K
  • Seqirus USA Inc$2K
  • AbbVie$295
  • Shionogi Inc$100
  • Merck$82
  • plus $185 from 4 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead226$1,002,005
Viiv Healthcare Company127$119,650
Seqirus USA Inc2$2,109
AbbVie(2 entities)6$295
Shionogi Inc1$100
Merck1$82
Janssen Products, LP1$82
GSK1$43
Pfizer2$41
Bavarian Nordic A/s1$19

How this compares

$1,124,425 in reported general payments places this provider in the 95th percentile of 90 infectious disease providers in Oregon.

See all infectious disease providers in Oregon

Medicare billing

Part B allowed, 2024
$34,199
Medicare patients
122
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →